ArticleFrontiers in genetics2026
Development and validation of a machine learning scoring system based on multi-dimensional metabolic signatures for invasive examination triage in intestinal diseases.
Article in Frontiers in genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) often present with overlapping gastrointestinal symptoms despite distinct pathophysiological mechanisms. Colonoscopy remains the diagnostic gold standard but is invasive, costly and frequently overutilized. Single biomarkers have limited diagnostic value because they do not fully reflect the complex metabolic and inflammatory alterations underlying intestinal diseases. We aimed to develop and validate an interpretable machine learning-based scoring system integrating multidimensional metabolism-related biomarkers for invasive examination triage. Methods: This retrospective single-center study included 729 participants (313 healthy controls, 210 IBS, 100 ulcerative colitis and 106 Crohn's disease patients) enrolled between July 2021 and November 2025. Demographic, clinical, and metabolism-related laboratory biomarkers reflecting inflammatory metabolism, nutritional metabolism, hepatic metabolic function, and renal metabolic homeostasis were collected. Correlation network analysis, least absolute shrinkage and selection operator (LASSO) regression, extreme gradient boosting (XGBoost), and a simplified nomogram-based scoring system were applied to differentiate IBD from non-IBD conditions. Results: Significant differences were observed across all clinical and metabolism-related variables (P < 0.001). IBD patients exhibited elevated inflammatory-metabolic-related biomarkers and dense inflammation-driven metabolic correlation networks, whereas IBS patients showed metabolic profiles similar to healthy controls. XGBoost achieved the best diagnostic performance (AUC = 0.992), followed by LASSO (AUC = 0.978). A simplified scoring system incorporating sex, age, log-transformed fecal calprotectin (Log Conclusion: IBD is characterized by distinct multidimensional metabolism-related biomarker signatures. The proposed machine learning-based scoring system integrates these metabolism-related biomarkers into a reliable, non-invasive tool for invasive examination triage, potentially reducing unnecessary colonoscopies and improving clinical resource utilization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.